xxxxxDNA
xxxxxDNA Articles
Genentech Inc. (NYSE: DNA) is initially looking like a severe disappointment to those who thought Cramer’s call last week was the right one. The largest biotech in the U.S. posted $0.82 EPS on...
Published:
Genentech Inc. (NYSE: DNA) is set to report earnings after the close of trading today. The largest biotech in the U.S. is expected to post $0.86 EPS on $3.23 Billion in revenues according to First...
Published:
These are ten of the analyst calls we are seeing early this Thursday morning in early bird pre-market trading hours: American International Group (NYSE: AIG) raised to Buy at Citigroup. Bare...
Published:
Last night was a novel release from the American Society of Clinical Oncology (or ASCO) as the society decided to publish all of the findings to the public at once. Keep in mind that many of the...
Published:
Last Updated:
Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) came out this morning with some disappointing news. The biotech giants have announced that a Phase II/III study of Rituxan for lupus...
Published:
Amylin Pharmaceuticals (NASDAQ: AMLN) reported first quarter losses of $68.8 million, or $0.51 EPS, wider than the $49.4 million in the first quarter of 2007. Losses are credited to a drop in sales...
Published:
Genentech, Inc. (NYSE:DNA) has announced that the biotech giant has authorized the extension of its current stock repurchase program through June 30, 2009 and it amended the current repurchase...
Published:
Last Updated:
According to Reuters, Bernanke says that the current financial system can be fixed. Reuters writes that Google (GOOG) is using Frank Quattrone as its investment bank advisor. Reuters reports that...
Published:
Shares of Genentech Inc. (NYSE: DNA) are trading slightly lower after reporting a gain in earnings. The biotech giant posted $0.74 net EPS, but non-GAAP EPS excluding special items was $0.84 EPS on...
Published:
Thursday after the close, we’ll get to see earnings out of Genentech (NASDAQ: DNA). The estimates from First Call are $0.82 EPS on $3.11 billion in revenues. Next quarter estimates are $0.86 EPS...
Published:
Biotech’s are sliding along with all the others today. A look at the highlights and outliers: Amgen (NASDAQ: AMGN) and Wyeth (NYSE: WYE) announced that arthritis and psoriasis drug Enbrel will now...
Published:
On tonight’s Mad Money on CNBC, Jim Cramer said he’s officially going "cautious" and noted that you can’t just start recommending stocks in the current market. He noted that we haven’t even...
Published:
Last Updated:
Below are the top research calls that a673b.bigscoots-temp.com is focusing on: Aventine Renewable Energy (NYSE: AVR) downgraded to Sell from Hold at Soleil. Genentech (NYSE: DNA) raised to Outperform at Rodman...
Published:
The FDA has approved Genentech’s (NYSE: DNA) drug Avastin for the treatment of breast cancer. The product is already Genentech’s top selling drug but is marketed for treating other cancers. Tests...
Published:
According to Reuters, ING took a Q4 impairment at the low end of expectations. Reuters writes that KKR Financial Holdings has delayed debt payments on loans backed by mortgge-related securities....
Published: